Do you want to read an article? Please log in or register.
Real-world outcomes of the mesenchymal stromal cell product tomostrocel in heavily pretreated pediatric patients with refractory acute graft-versus-host disease
Further Publications
Related content
Lymphoma
Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting
Br J Haematol
Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW
doi: 10.1111/bjh.70632
Lymphoma
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Blood
Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I
doi: 10.1182/blood.2025031733
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Leukemia
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study
Br J Haematol
Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F, German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)
doi: 10.1111/bjh.70735
Leukemia
Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse
Am J Hematol
Tsirigotis P, Garofalaki M, Lazana I, Liga M, Gigantes S, Kopsaftopoulou A, Tziotziou E, Roumelioti A, Tsintziloni E, Hatzis S, Konstantellos I, Benetatos L, Barbarousi D, Tzenou T, Asimakopoulos JV, Karagiannidi A, Barakos G, Delimpasi S, Stoumbos D, Stamouli M, Plata E, Valera K, Giannouli S, Chatzidimitriou C, Gkolfinopoulou G, Siakantaris MP, Kotsopoulou M, Voulgarelis M, Chondropoulos S, Zina V, Gkirkas K, Kapsali E, Matsouka C, Vassilakopoulos TP, Spyridonidis A, Angelopoulou M, Baltadakis I
doi: 10.1002/ajh.70322
Multiple Myeloma (MM)
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium
Blood Cancer J
Varga C, Robinson M, Davis JA, Hashmi H, Martin TG, Kumar A, Sborov DW, Wagner CB, Hansen DK, Castaneda Puglianini O, Shune L, Bhurtel E, Afrough A, Anderson LD Jr, Dhakal B, Herr MM, Richard S, Lieberman-Cribbin A, Sherbenou D, Forsberg PA, Purvey S, Khouri J, Lin Y, Sidana S, Patel KK, Kocoglu M, Midha S, Ferreri CJ
doi: 10.1038/s41408-026-01469-z
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung, Respiratory and Thoracic Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762
Further Publications
Low-dose ruxolitinib for graft-versus-host disease prevention in haploidentical haematopoietic stem-cell transplantation: a multicentre, open-label, randomised, controlled, phase 3 trial
Lancet Haematol
Wu H, Shi W, Shi Z, Luo Y, Yu J, Cao W, Cao J, Xu X, Hu X, Lu Y, Fu H, Liu L, Lai X, Yang L, Ye Y, Zhang C, Shi J, Huang H, Zhao Y
doi: 10.1016/S2352-3026(26)00167-5